Skip to main content

cardiac arrhythmia Archives

A clue to an adverse drug event in children

May. 19, 2022—Considering metabolic (CYP2D6) enzyme activity score and patient age may aid in determining an individual’s risk for an adverse event with administration of the anti-arrhythmic drug propafenone.

Read more


Studies combine genetic testing, electronic health records to find undiagnosed diseases

Apr. 28, 2022—Combining genetic testing with information from electronic health records revealed undiagnosed heart rhythm disorders and new conditions associated with inherited cancer gene mutations.

Read more


VHVI offers latest therapies to treat atrial fibrillation

Sep. 9, 2021—Vanderbilt Heart and Vascular Institute continues to offer the latest in therapies to treat atrial fibrillation (AF or AFib), the most common cardiac arrhythmia.

Read more


Arrhythmia culprit: supertrafficking ion channel

Apr. 15, 2021—Charles Sanders, PhD, and colleagues show how a “supertrafficking” mutant potassium channel contributes to heart rhythm abnormalities.

Read more


Minimally invasive treatment option for AFib studied

Oct. 22, 2020—A minimally invasive procedure that combines ligation of the left atrial appendage (LAA) with hybrid epicardial-endocardial ablation is a feasible, safe and effective method of treating patients with longstanding atrial fibrillation (AF or AFib), according to a new Vanderbilt-led study.

Read more


Risk factors for faulty rhythms

Aug. 16, 2018—Risk factors for arrhythmias after heart surgery in infants include medications, infant age and higher surgical complexity, but not two genetic variants examined by Vanderbilt researchers.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more